title: Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease.
abstract: BACKGROUND
  Inflammatory bowel disease (IBD) present in childhood in 15% to 25% of cases. The aim of therapy in children is not only to guarantee normal growth but also to prevent relapse and to maintain remission. Steroids are effective to induce remission; however, resistance, dependency, and irreversible side effects can develop. The aim of this study was to determine whether treatment with repeated infusions of autologous red blood cells (RBCs) loaded with dexamethasone 21-phosphate (Dex 21-P) is safe and allows maintenance of long-term remission in children with steroid-dependent Crohn disease (CD).
  
  
  METHODS
  Eighteen consecutive pediatric patients who met the inclusion criteria were admitted to the study. Infusions of autologous RBCs loaded with Dex 21-P were performed every 4 weeks; the mean duration of treatment was 24 months. At the beginning of treatment and after 6, 12, and 24 months, we performed clinical evaluation according to the Pediatric Crohn Disease Activity Index (pCDAI). Assessment of body mass in dexamethasone and bone mineral density by means of computerized bone mineralometry-dual energy x-ray absorptiometry, endoscopic evaluation, and hematic morning cortisol determination were also performed.
  
  
  RESULTS
  During treatment, the mean pCDAI significantly decreased (P < 0.05); 78% of patients discontinued steroids. Determination of morning cortisol showed suppression only on the first day after infusion, followed by normalization of values. Endoscopic findings showed remission in 44% of patients. None of the patients experienced serious side effects.
  
  
  CONCLUSIONS
  These data suggest that repeated infusions of RBCs loaded with Dex 21-P can be safe and useful to maintain long-term remission in pediatric patients with moderately active CD.
authors.affiliation: Gastroenterology Unit, Bambino Gesù Children's Hospital, Rome, Italy. castro@opbg.net
authors.forename: M
authors.initials: M
authors.lastname: Castro
authors.forename: L
authors.initials: L
authors.lastname: Rossi
authors.forename: B
authors.initials: B
authors.lastname: Papadatou
authors.forename: F
authors.initials: F
authors.lastname: Bracci
authors.forename: D
authors.initials: D
authors.lastname: Knafelz
authors.forename: M I
authors.initials: MI
authors.lastname: Ambrosini
authors.forename: A
authors.initials: A
authors.lastname: Calce
authors.forename: S
authors.initials: S
authors.lastname: Serafini
authors.forename: G
authors.initials: G
authors.lastname: Isacchi
authors.forename: F
authors.initials: F
authors.lastname: D'Orio
authors.forename: G
authors.initials: G
authors.lastname: Mambrini
authors.forename: M
authors.initials: M
authors.lastname: Magnani
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001804:Blood Transfusion, Autologous; D002648:Child; D002675:Child, Preschool; D003424:Crohn Disease / Q000628:therapy*; D003907:Dexamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017707:Erythrocyte Transfusion / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D012074:Remission Induction
chemical_list: D000893:Anti-Inflammatory Agents; C004180:dexamethasone 21-phosphate; D003907:Dexamethasone